A Twitter exchange led to Cuban's fund, Radical Investments, putting $250,000 into Perlara's $7.4 million fundraising round. Now, Cuban's investing again to find treatments for an extremely rare disease called Leigh syndrome. » Read More
By: Elizabeth Gurdus
Jim Cramer reveals how Bausch Health has put together an amazing comeback. » Read More |
By: Thomas Franck
Marijuana producer Tilray reported quarterly earnings that beat analysts' expectations on Tuesday, though total revenues fell just shy of estimates. » Read More |
By: Tyler Clifford
Amarin CEO is defending results from a major clinical trial of its Vascepa heart drug after researchers raise questions about early results that sent stocks up in September. » Read More |
Aurora Cannabis reported on Monday that revenue jumped 260 percent over the last 12 months, with kilograms produced climbing to 4,996 from 1,010 over the past year.
Jim Cramer explains how a strong consumer snapshot could force an ugly reaction from the Fed.
Investors should concentrate and then capitalize on the year-end bounce in technology stocks, Fundstrat technical strategist Robert Sluymer says.
Health care was the top issue for Americans voting in Tuesday's midterm elections.
Health care was the top issue for Americans voting in Tuesday's midterm elections.
President Trump says at a White House press conference he hopes to work with congressional Democrats on issues ranging from infrastructure to drug pricing.
The midterm election results are a win for the marijuana industry, according to the CEO of a prominent cannabis company.
Rep. Chris Collins, the Republican recently indicted on federal insider trading charges, will retain his House seat representing New York's 27th District.
Michigan voters authorize the legalization of possession, use and cultivation of marijuana products by those at least 21 years old.
The flu vaccine isn't perfect, but it's still the best way to protect yourself and others from influenza.
Jim Cramer warns investors not to panic in the wake of Apple's earnings.
Jim Cramer hears from GW Pharmaceuticals CEO Justin Gover about his company's cannabis-based epilepsy treatment that just launched in the United States.
Jim Cramer issues a warning to investors about the pharmaceutical sector, which includes high-profile stocks like Allergan and Gilead.
BMO Capital Markets downgrades Pfizer and says shares of the pharmaceutical giant should take a breather from their strong run over the last 12 months.
Shares of Esperion popped on the company's latest data for its cholesterol drug.
Jim Cramer breaks down the action in Facebook's stock after its earnings report.
Get the best of CNBC in your inbox
Data also provided by 
